QC specifications for EconoTaq are rigorous:

• Greater than 99% pure by SDS gel electrophoresis (see Figure 1).
• No detectable DNA contamination as determined by PCR using generic primers.
• No detectable endonuclease (nicking) activity. Incubation of 10 U of EconoTaq DNA Polymerase with 1 µg of supercoiled pBR322 DNA for 16 hours at 70°C results in no detectable conversion to relaxed or linear forms by agarose gel electrophoresis.
• No detectable exonuclease activity. Incubation of 10 U of EconoTaq DNA Polymerase with 1 µg of Hind III-cut lambda DNA for 16 hours at 70°C results in no smearing of bands on agarose gels.

EconoTaq Performance
As shown in Figures 2 and 3 Lucigen’s EconoTaq DNA Polymerase performs as well as, or better than, more expensive Taq preparations from several other suppliers in routine PCR. EconoTaq is as effective in DNA amplification as another standard PCR enzyme, Tfl DNA polymerase (Figure 4). In this case, the background of non-specific amplification was much lower with EconoTaq (compare “+”and “–“ lanes for EconoTaq and Tfl in Figure 4). EconoTaq DNA Polymerase also offers high lot-to-lot reproducibility and reliability (Figures 2 and 4)

Figure 1. High purity of EconoTaq DNA Polymerase (SDS PAGE). Lane 1, broad range molecular weight markers; Lane 2, Lucigen EconoTaq DNA Polymerase	Figure 2. Taq DNA polymerase from Promega and New England Biolabs were compared to Lucigen’s EconoTaq DNA Polymerase (2 different lots) in amplifying the ampicillin gene (0.8 kb) in a pUC19 vector. (–), no DNA. (+), DNA added (40 ng). MW, 1 kb ladder.

Please Note:
Some applications in which Lucigen's EconoTaq DNA Polymerase can be used may be covered by patents issued and applicable in the United States and certain other countries. Because purchase of this product does not include a license to perform any patented application, users of this product may be required to obtain a patent license depending upon the particular application in which the product is used. The PCR process is the subject of European Patent Nos. 201,184 and 200,262 owned by Hoffman-LaRoche. Those patents expired on March 28, 2006. The corresponding PCR process patents in the United States expired on March 29, 2005. It is the sole responsibility of the buyer to ensure that use of the product does not infringe the patent rights of third parties.